(19)
(11) EP 4 823 679 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24837771.5

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
A61P 25/16(2006.01)
A61P 37/00(2006.01)
C07D 487/04(2006.01)
C07D 473/00(2006.01)
A61P 25/28(2006.01)
C07D 471/04(2006.01)
C07D 519/00(2006.01)
C07D 513/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 487/04; C07D 471/04; C07D 473/00; C07D 513/04; A61P 25/16; A61P 25/28; A61P 37/00
(86) International application number:
PCT/US2024/059856
(87) International publication number:
WO 2025/128873 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 12.12.2023 US 202363609320 P
12.12.2023 US 202363609327 P

(71) Applicant: Vigil Neuroscience, Inc.
New Jersey 07960 (US)

(72) Inventors:
  • HOUZE, Jonathan B.
    Morristown, New Jersey 07960 (US)
  • PANDYA, Bhaumik
    Morristown, New Jersey 07960 (US)

(74) Representative: Ipsilon 
12 Avenue d'Italie
75013 Paris
75013 Paris (FR)

   


(54) HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE